|
Search
Collections
Benchmarks
Upload document
Organization
University Hospital of Zürich
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 poster
Poster
AcceleRET Lung: a phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC
